Brief: Ryvu Therapeutics Clinical and Translational Data Is Accepted For Presentation in US

Ryvu Therapeutics SA

04/11/2021 14:36

Nov 4 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * ANNOUNCES THAT 5 ABSTRACTS DEMONSTRATING CLINICAL AND
PRECLINICAL ACTIVITY OF SELECTIVE CDK8/19 INHIBITOR RVU120
SEL120) AND SELECTIVE PIM/FLT3 INHIBITOR SEL24 (MEN1703) ARE
ACCEPTED FOR PRESENTATION
    * PRESENTATION TO BE HELD ON DEC 11 - DEC 14 IN ATLANTA
(USA) AT
63RD AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING &
EXPOSITION

Source text for Eikon:  ID:nEM3SQ7hJa 
Further company coverage:  RVU.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))